ResMed eyes rebound as market ignores strong fundamentals

The gist
Despite robust profits and fresh leadership, ResMeds stock is languishing well below its true value as Wall Street fixates on risks over fundamentals.
What to know
- Shares trade 32% below intrinsic value ($325) even as ResMed posts $1.66B in free cash flow and a 27% net margin.
- Governance shakeupsincluding Carol Burt as Lead Director and PwC replacing KPMGsparked an 18.56% one-month rally amid longer-term declines.
- A high-profile NASCAR sleep apnea campaign and a pivotal wearable device trial headline ResMeds push for growth, even as market skepticism persists.
Valuation Disconnect Persists
ResMed’s strong cash flow and profitability are at odds with its depressed share price, as market doubts over future growth and recalls overshadow robust fundamentals.
Despite a 22.4% decline over the past year, ResMed's stock appears significantly undervalued, trading roughly 32% below its intrinsic value estimated at $325 per share via a Discounted Cash Flow model. This undervaluation is supported by the company's robust free cash flow generation of approximately $1.66 billion over the last twelve months, suggesting sustained earnings power if cash flow growth continues steadily rather than relying on a sharp rebound.
Market skepticism stems from a softer FY27 revenue outlook, a Class 1 ventilator recall, and ongoing cost pressures, which have pushed ResMed's price-to-earnings ratio to about 20.9x—below both the Medical Equipment industry average of 26.0x and peer average of 28.9x. This valuation discount persists despite the company’s strong profitability metrics, including a net margin near 27% and return on equity exceeding 25%, underscoring a disconnect between fundamentals and market pricing.
Investor sentiment remains divided, with some bullish on underappreciated demand in the growing sleep health sector, while others remain cautious due to supply chain concerns and valuation risks. This ambivalence is reflected in the stock’s recent trading in the mid-$230s, down more than 6% from recent highs, and a modest consensus analyst price target of $239.38, signaling limited upside amid persistent market uncertainty.
ResMed’s solid operational performance, including a 9% rise in Q4 revenue, earnings per share beating estimates at $2.95 versus $2.89 expected, and a 10% dividend increase to $0.66 per share, contrasts sharply with the stock’s downward price pressure. This divergence highlights ongoing market skepticism that weighs near-term challenges more heavily than the company’s demonstrated growth and shareholder returns.
Governance Shakeup Spurs Optimism
A sweeping board refresh and auditor switch have reignited investor confidence, fueling a rapid share price rebound even as long-term performance lags.
In 2026, ResMed undertook significant governance restructuring by appointing Carol Burt as Lead Director effective November and replacing KPMG with PricewaterhouseCoopers as its independent auditor. These moves signal a deliberate reshaping of the company’s governance framework aimed at bolstering credibility and aligning leadership with strategic priorities, reflecting a broader effort to enhance investor confidence amid market challenges.
The timing of these governance changes coincides with a notable uptick in share price momentum, as ResMed’s stock posted an 18.56% return over one month despite a year-to-date decline of 5.43% and a longer-term 18.14% drop over the past year. This juxtaposition suggests that investors are responding positively to the governance overhaul, interpreting it as a signal of management’s commitment to strategic renewal even as the company navigates mixed longer-term performance.
ResMed’s governance updates are part of a coordinated strategy that pairs board and auditor changes with a high-profile sleep apnea awareness campaign through NASCAR sponsorship. This integrated approach aims to simultaneously elevate the company’s public profile and reinforce governance credibility, thereby attracting investor attention and potentially catalyzing a more sustained positive shift in share price momentum.
Growth Bets: NASCAR to Wearables
ResMed is doubling down on awareness campaigns and next-gen device trials to boost demand and innovation, reinforcing its leadership in sleep health despite market headwinds.
ResMed is strategically leveraging high-profile partnerships, such as with NASCAR driver Tyler Reddick, to elevate public awareness of sleep apnea and drive increased diagnosis and therapy adoption. By spotlighting a recently treated patient to millions of fans, the company aims to sustain demand for its devices amidst reimbursement pressures and competitive threats, positioning awareness as a critical growth catalyst.
Complementing its marketing initiatives, ResMed is advancing clinical innovation through a pivotal trial of a wearable positive airway pressure device, signaling a potential transformation of its sleep apnea treatment portfolio. This next-generation technology, alongside investments in cloud-connected platforms, underscores the company’s commitment to long-term growth while balancing shareholder returns, as evidenced by a recent 10% dividend increase to $0.66 per share amid robust 20%-plus net margins.